WO2004010932A3 - Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions - Google Patents

Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions Download PDF

Info

Publication number
WO2004010932A3
WO2004010932A3 PCT/US2003/023326 US0323326W WO2004010932A3 WO 2004010932 A3 WO2004010932 A3 WO 2004010932A3 US 0323326 W US0323326 W US 0323326W WO 2004010932 A3 WO2004010932 A3 WO 2004010932A3
Authority
WO
WIPO (PCT)
Prior art keywords
suicide
depression
prevention
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/023326
Other languages
French (fr)
Other versions
WO2004010932A2 (en
Inventor
Peter Migaly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to MXPA05000294A priority Critical patent/MXPA05000294A/en
Priority to CA002529857A priority patent/CA2529857A1/en
Priority to AU2003268026A priority patent/AU2003268026A1/en
Priority to EP03748977A priority patent/EP1551393A4/en
Publication of WO2004010932A2 publication Critical patent/WO2004010932A2/en
Publication of WO2004010932A3 publication Critical patent/WO2004010932A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, nonpsychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and/or using the method for smoking cessation or nicotine withdrawal.
PCT/US2003/023326 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions Ceased WO2004010932A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA05000294A MXPA05000294A (en) 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions.
CA002529857A CA2529857A1 (en) 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AU2003268026A AU2003268026A1 (en) 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP03748977A EP1551393A4 (en) 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31943602P 2002-07-30 2002-07-30
US60/319,436 2002-07-30

Publications (2)

Publication Number Publication Date
WO2004010932A2 WO2004010932A2 (en) 2004-02-05
WO2004010932A3 true WO2004010932A3 (en) 2004-07-22

Family

ID=31188203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023326 Ceased WO2004010932A2 (en) 2002-07-30 2003-07-25 Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Country Status (6)

Country Link
US (2) US7973043B2 (en)
EP (1) EP1551393A4 (en)
AU (1) AU2003268026A1 (en)
CA (1) CA2529857A1 (en)
MX (1) MXPA05000294A (en)
WO (1) WO2004010932A2 (en)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
JP2005504783A (en) * 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト Optical isomers of iloperidone metabolites
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20030092770A1 (en) * 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
PT1578422E (en) 2002-12-20 2007-06-14 Niconovum Ab PARTICULATE MATERIAL CONTAINING NICOTINE PHYSICALLY AND CHEMICALLY STABLE
KR100842694B1 (en) 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (en) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd COMBINATION OF CARBOSTIRILE DERIVATIVES AND INHIBITORS OF SEROTONINE REABSORTION FOR THE TREATMENT OF ANIMO DISORDERS
EP2260844A1 (en) * 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James Combination therapy for dementia,depression and apathy
UY28650A1 (en) * 2003-12-05 2005-02-28 Forest Laboratories MEMANTINE FOR THE PREVENTION OR DECREASE OF SUICIDE CONDUCT AND FOR THE TREATMENT OF THE MAJOR DEPRESSION ASSOCIATED WITH THIS CONDUCT
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20050181071A1 (en) * 2004-02-18 2005-08-18 Binder Michael R. Method for the treatment of clinical depression
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Lithium combinations, and uses related thereto
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
JP2008519055A (en) * 2004-11-08 2008-06-05 シャイア エルエルシー Synergistic effect of combined administration of mirtazapine and stimulant complex
US20060150989A1 (en) * 2005-01-12 2006-07-13 Peter Migaly Method of diagnosing, treating and educating individuals with and/or about depression
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2009503020A (en) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of flibanserin in the treatment of obesity
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
EP1948238B1 (en) * 2005-11-10 2013-08-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
CN101062039B (en) * 2006-04-30 2010-05-12 北京华安佛医药研究中心有限公司 Pharmaceutical composition for treating nervous system diseases
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
GB0712101D0 (en) * 2007-06-22 2007-08-01 Therapeutics Ltd E Treatment of depression
CL2008002693A1 (en) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
WO2009067607A2 (en) * 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
GB0811024D0 (en) * 2008-06-17 2008-07-23 E Therapeutics Plc Sustained release treatment of depression
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2582375A4 (en) 2010-06-16 2013-12-25 Embera Neurotherapeutics Inc COMPOSITIONS AND METHODS FOR TREATING SEARCH, PSYCHIC DISORDER AND NEURODEEGENERATIVE DISEASES
CA2733956A1 (en) 2011-03-10 2012-09-10 Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compositions and methods for modulating circadian synchronization
CN102680636A (en) * 2011-03-11 2012-09-19 天津药物研究院 Iloperidone active pharmaceutical ingredient (API) and quality control method for intermediate thereof
RU2465603C1 (en) * 2011-06-15 2012-10-27 Федеральное государственное учреждение "Московский научно-исследовательский институт психиатрии" Министерства здравоохранения и социального развития Российской Федерации Method for prediction of clinical effectiveness in non-psychotic versions of psycho-organic syndrome
US8514067B2 (en) 2011-08-16 2013-08-20 Elwha Llc Systematic distillation of status data relating to regimen compliance
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK2983787T3 (en) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Procedure for the treatment of post-traumatic stress disorder
EP3024451A4 (en) * 2013-06-24 2017-08-16 The Johns Hopkins University Methods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors
HUE056378T2 (en) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp Application of r-ketamine and salt thereof as pharmaceuticals
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US20200261431A1 (en) 2019-01-07 2020-08-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
WO2015089494A1 (en) * 2013-12-13 2015-06-18 Ankenman Ralph Compositions and methods for treating dysregulated systems
KR20170040800A (en) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
ES2945599T3 (en) 2014-09-23 2023-07-04 Icahn School Med Mount Sinai Systems and methods for the treatment of a psychiatric disorder
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US10702512B2 (en) 2015-05-13 2020-07-07 A. Carlsson Research Ab Treatment of debilitating fatigue
CN107847469A (en) 2015-06-27 2018-03-27 美国神农制药责任有限公司 Ketamine transdermal delivery system
JP2019501119A (en) * 2015-11-09 2019-01-17 ザ マクレーン ホスピタル コーポレーション Methods and compositions for preventing suicide, murder, and self-injurious behavior
US9609121B1 (en) 2016-04-07 2017-03-28 Global Tel*Link Corporation System and method for third party monitoring of voice and video calls
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN115813888A (en) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 Transdermal therapeutic system containing asenapine
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
US20180293682A1 (en) * 2017-04-05 2018-10-11 Global Tel*Link Corporation System and method for providing suicide prevention and support
US10860786B2 (en) 2017-06-01 2020-12-08 Global Tel*Link Corporation System and method for analyzing and investigating communication data from a controlled environment
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
MA50786A (en) 2017-10-26 2022-04-27 Blumentech S L COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS
KR20240011237A (en) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 Esketamine for the treatment of depression
ES2907692T3 (en) 2017-12-29 2022-04-26 Celon Pharma Sa Composition of dry powder ketamine for pulmonary administration in treatment-resistant depression
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020006367A1 (en) * 2018-06-29 2020-01-02 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
JP2022524008A (en) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド Esketamine for the treatment of depression
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
KR20220049407A (en) 2020-10-14 2022-04-21 삼성전자주식회사 Display apparatus and control method thereof
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
EP4240486A4 (en) * 2020-11-06 2024-05-22 EIP Pharma, Inc. Treatment of gait dysfunction in neurodegenerative disease
JP2024512796A (en) * 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． Methods and compositions for psychedelic drugs and serotonin receptor modulators
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
US20250011351A1 (en) 2021-11-12 2025-01-09 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US20240350483A1 (en) * 2023-04-12 2024-10-24 GSKB Pharmaceuticals, LLC Combination therapy for the treatment of psychiatric disorder
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
CN118553447B (en) * 2024-07-30 2024-11-08 四川大学华西医院 Dynamic panic disorder treatment scheme recommendation system, treatment system and storage medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
HUP9903684A3 (en) * 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA989251B (en) 1997-10-17 2000-04-10 Lilly Co Eli Potentiation of pharmaceuticals.
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
SK14502000A3 (en) 1998-05-08 2001-05-10 Pharmacia And Upjohn Company New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
HUP0101901A3 (en) 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911068A (en) 1998-05-29 2001-02-06 Lilly Co Eli Combination therapy for the treatment of bipolar disorders
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
JP2002530340A (en) 1998-11-23 2002-09-17 セプラコール， インク． Pharmaceutical composition containing olanzapine-N-oxide
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
AU3757500A (en) 1999-03-18 2000-10-04 Childrens Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
CA2431041A1 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (en) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd RECEIVER SUBTIPE AGONIST 5-HT 1A.
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1551393A2 *

Also Published As

Publication number Publication date
WO2004010932A2 (en) 2004-02-05
AU2003268026A1 (en) 2004-02-16
US20040204401A1 (en) 2004-10-14
EP1551393A4 (en) 2010-06-16
CA2529857A1 (en) 2004-02-05
US7973043B2 (en) 2011-07-05
AU2003268026A8 (en) 2004-02-16
US20120289515A1 (en) 2012-11-15
EP1551393A2 (en) 2005-07-13
MXPA05000294A (en) 2005-08-19

Similar Documents

Publication Publication Date Title
WO2004010932A3 (en) Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
Bernal-Pacheco et al. Nonmotor manifestations in Parkinson disease
Lieberman History of the use of antidepressants in primary care
WO2004043341A3 (en) Treatment for hemorrhagic shock
MX2007001679A (en) Prevention and treatment of synucleinopathic and amyloidogenic disease.
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2001026623A3 (en) Treatment of fatigue, head injury and stroke
MX2010002498A (en) Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol.
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2003072024A3 (en) Methods of treating vascular disease
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
MY152919A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
NO20064964L (en) Treatment of impaired respiratory function
Durgam et al. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
WO2010045522A3 (en) Combination therapies for the treatment of obesity
Oelke et al. Safety and tolerability of duloxetine in women with stress urinary incontinence
UA89753C2 (en) Use of a modafinil and an antidepressant for the treatment of depression and for decreasing the onset time of an antidepressant
UA84692C2 (en) Pharmaceutical composition, comprising aripiprazole and serotonin reuptake inhibitor, and the use thereof for treatment of mood disorders
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
NO20005223L (en) Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon
WO2007035879A3 (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
AP2004003113A0 (en) Use of an inhibitor or antagonist against tissue factor
CA2338327A1 (en) Use of moclobemide for treating pain and other diseases
IL162391A0 (en) Method of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000294

Country of ref document: MX

Ref document number: 2003748977

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003748977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2529857

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP